查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992428

人工心臟市場：按類型、應用、技術、最終用戶和患者群體分類－2026-2032年全球市場預測

Artificial Heart Market by Type, Application, Technology, End User, Patient Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工心臟市場價值將達到 31.4 億美元，到 2026 年將成長至 34.8 億美元，到 2032 年將達到 68.1 億美元，複合年成長率為 11.67%。

主要市場統計數據
基準年 2025 31.4億美元
預計年份：2026年 34.8億美元
預測年份 2032 68.1億美元
複合年成長率 (%) 11.67%

此資源涵蓋了人工心臟不斷發展的現狀，包括臨床需求、創新趨勢、監管複雜性和支付方考慮因素，為醫療保健相關人員。

人工心臟領域正處於緊迫的臨床需求、技術創新和複雜的法律規範三者交匯的境地。近年來，設備耐用性、小型化和遠端監測方面的進步，已使這項技術從實驗性治療方法轉變為針對特定患者群體的實用、長期機械循環支持手段。同時，臨床醫生和醫療保健系統面臨著不斷變化的臨床指南、日益重視的感染控制和抗凝血治療，以及透過療效和成本效益指標來證明其價值的日益成長的壓力。

識別正在重塑人工心臟發展的變革性變化，包括小型化、耐用的機械循環支援平台、數位化整合以及增強臨床效用的新型生物相容性材料。

多項變革正在重塑人工心臟生態系統，在創造新機會的同時，也重塑了競爭格局。首先，小型化和能源效率的技術進步使得人工心臟能夠實現更小的外形規格和攜帶式使用，從而惠及更廣泛的患者群體，並改變了植入手術的物流。同時，生物相容性塗層和血液相容性的改善降低了血栓形成和感染相關併發症的風險，也改變了人們對長期管理和追蹤通訊協定的預期。

評估美國關稅對人工心臟供應鏈、採購趨勢、臨床准入途徑以及製造商和供應商對策略定價的應對措施的累積影響。

美國2025年實施的關稅和貿易政策轉變將對人工心臟供應鏈、籌資策略和臨床應用模式產生多方面的影響。關稅將增加許多先進醫療設備製造商賴以生存的進口零件和子組件的到貨成本。對於那些從海外採購專用感測器、電機用稀土元素材料或精密加工零件的企業而言，這種影響尤其顯著。因此，製造商被迫透過重新評估供應商組合、加快國內供應商的認證流程或調整內部利潤率等措施來承擔增加的成本。

為了明確設備類型、應用、技術、最終用戶和患者人口統計的實際細分見解，並將這些見解反映在產品設計、臨床引入和市場發布策略中。

精細化的市場區隔觀點能夠清楚展現臨床需求、技術能力和商業性機會的契合點。基於類型，市場分析將產品分為“人工心臟”和“心室輔助裝置”，其中心室輔助裝置進一步細分為“雙心室輔助裝置”、“左心室輔助裝置”和“右心室輔助裝置”，以反映不同的臨床適應症和植入複雜性。每種裝置亞型都具有獨特的技術權衡、後續要求和臨床培訓項目，這些因素共同決定了其在醫療機構中的部署模式。

確定美洲、歐洲、中東、非洲和亞太地區的關鍵區域因素，並協調監管流程、償還模式和商業化計畫。

區域趨勢對監管時間表、報銷方式和臨床應用有顯著影響。在美洲，集中且高品質的醫療中心、成熟的移植項目以及完善的醫院採購流程，為高成本、高複雜度的醫療器材的推廣創造了有利條件；與此同時，區域保險公司也越來越要求在核准報銷前提供強力的治療效果證據。此外，在有影響力的學術機構的主導下，北美臨床網路往往能夠促進創新技術的採納，而採購主導的聯合採購則可以加速整個醫療系統的大規模應用。

本報告重點介紹了在人工心臟生態系統中塑造領導地位的企業層面的競爭與合作趨勢、策略夥伴關係、智慧財產權趨勢和投資模式。

人工心臟領域的企業活動呈現兩種發展軌跡：一是成熟醫療設備製造商的持續投資，二是專業Start-Ups和大學衍生企業的敏捷創新。成熟公司通常專注於透過臨床試驗逐步改進，提高可靠性、減少不利事件並擴大適應症。同時，中小企業和大學附屬團隊則往往致力於突破性概念的研發，例如新型泵結構、替代能量傳輸機製或可最大限度減少宿主反應的生物材料，這些都可能成為戰略夥伴關係和許可協議的理想目標。

為醫療設備製造商、臨床領導者和支付方提供可操作的建議，以加快採用速度、最佳化價值提案並減少供應鏈和監管摩擦。

行業領導者可以採取多項切實可行的措施來加速技術應用並保持商業性發展勢頭。製造商應優先考慮模組化設計原則，以減少對關稅敏感組件的依賴，並簡化分階段改進的監管申報流程。確保使用檢驗的替代供應商並對本地製造合作夥伴進行認證，可以降低供應鏈中斷的風險，同時確保產品上市時間。此外，投資遙測和結果平台可以透過產生真實世界數據 (REW) 來提供競爭優勢，而支付方和醫療保健系統對此類數據的需求日益成長。

我們將解釋我們嚴謹的混合調查方法，該方法整合了臨床證據評估、相關人員訪談、供應鏈分析和監管映射，以確保可靠的市場情報。

本研究採用混合調查方法，旨在透過交叉檢驗臨床、商業性和監管觀點，得出可靠且可操作的見解。此方法首先對同行評審的臨床文獻、監管申報文件和已發布的指南進行全面評估，以建立醫療設備安全性、有效性和適應症的證據基礎。為了補充這一證據基礎，研究人員還與包括心胸外科醫生、心臟衰竭專家、醫院採購經理、保險公司和醫療設備工程師在內的關鍵相關人員進行了結構化訪談，以收集實際見解和營運限制。

這項見解綜合了技術、監管和商業性趨勢，為人工心臟領域的策略決策和未來投資重點提供了指導。

技術成熟、臨床通訊協定不斷演進以及商業性趨勢的轉變，共同將人工心臟技術推向了轉折點。設備工程和遙測技術的進步正在穩步降低傳統上阻礙人工心臟廣泛應用的障礙，但區域法規和醫療保險報銷環境仍然影響著人工心臟的部署速度和模式。供應鏈壓力和貿易政策的變化增加了複雜性，要求各機構透過多元化經營和短期營運規劃來積極應對這些挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工心臟市場：依類型分類

  • 全人工心臟
  • 心室輔助裝置
    • 雙心室輔助裝置
    • 左心室輔助裝置
    • 右心室輔助裝置

第9章：人工心臟市場：依應用領域分類

  • 移植前的過渡治療
  • 最終治療

第10章：人工心臟市場：依技術分類

  • 軸流式
  • 離心式
  • 電磁
  • 氣動型

第11章 人工心臟市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：依患者群體分類的人工心臟市場

  • 成人
  • 兒童

第13章 人工心臟市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 人工心臟市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 人工心臟市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國人工心臟市場

第17章：中國人工心臟市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • BIOTRONIK SE & Co. KG
  • BiVACOR Inc.
  • Boston Scientific Corporation
  • Calon Cardio-Technology Ltd.
  • CARMAT SA
  • CorWave SA
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Evaheart, Inc.
  • FineHeart SA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Lepu Medical Technology Beijing Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • RealHeart AB
  • ReliantHeart, Inc.
  • Siemens Healthineers
  • Sun Medical Technology R&D Co., Ltd
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-3204321AF691

The Artificial Heart Market was valued at USD 3.14 billion in 2025 and is projected to grow to USD 3.48 billion in 2026, with a CAGR of 11.67%, reaching USD 6.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.14 billion
Estimated Year [2026] USD 3.48 billion
Forecast Year [2032] USD 6.81 billion
CAGR (%) 11.67%

Framing the evolving artificial heart landscape through clinical demand, innovation trajectories, regulatory complexities and payer considerations to orient strategic decision-making across healthcare stakeholders

The artificial heart landscape sits at the intersection of acute clinical need, engineering innovation and complex regulatory oversight. Recent advances in device durability, miniaturization and remote monitoring have elevated the technology from experimental therapy toward viable long-term mechanical circulatory support for selected patient populations. At the same time, clinicians and health systems face evolving clinical guidelines, intensified focus on infection control and anticoagulation management, and mounting pressure to demonstrate value through outcomes and cost-effectiveness metrics.

This introduction synthesizes the key forces shaping device development and clinical adoption, framing how improvements in biocompatible materials, power management and digital telemetry are unlocking new care pathways. It establishes the context for strategic decision-making by manufacturers, hospital procurement teams and clinical leaders, emphasizing the need for integrated planning across R&D, regulatory strategy and health economics. By highlighting the prevailing clinical imperatives and the technological enablers that respond to them, this section sets the stage for deeper analysis of market dynamics, segmentation drivers and region-specific considerations that follow.

Identifying transformative shifts reshaping artificial heart development including miniaturization, durable mechanical circulatory support platforms, digital integration and novel biocompatible materials driving clinical utility

Several transformative shifts are redefining the artificial heart ecosystem, creating new opportunities while resetting competitive imperatives. First, engineering advances in miniaturization and power efficiency are enabling smaller form factors and ambulatory use, which in turn broaden candidate profiles and alter implantation logistics. Concurrently, improvements in biocompatible coatings and hemocompatibility have reduced thrombotic risk and infection-related complications, changing long-term management expectations and follow-up protocols.

Digital integration is another pivotal trend: the embedding of telemetry, remote monitoring and predictive analytics into device platforms supports proactive clinical interventions, reduces readmissions and enables data-driven value demonstrations to payers. On the regulatory front, accelerated approval pathways and more harmonized international standards are shortening time-to-clinic for incremental device updates, even as scrutiny around safety and post-market surveillance intensifies. Finally, the convergence of novel financing models, growing private capital interest and strategic partnerships between device specialists and broader medtech or technology firms is reshaping product roadmaps and commercialization strategies. Together, these shifts are transitioning artificial heart technologies from niche salvage therapies to increasingly mainstream options within complex heart-failure care pathways.

Assessing cumulative impact of United States tariffs on the artificial heart supply chain, procurement dynamics, clinical access pathways and strategic pricing responses by manufacturers and providers

The imposition of tariffs and trade policy shifts in the United States in 2025 has a multi-dimensional effect on the artificial heart supply chain, procurement strategies and clinical access models. Tariffs increase the landed cost of imported components and subassemblies that many advanced device manufacturers rely upon, particularly when specialized sensors, rare-earth materials for motors, or precision machining are sourced internationally. The immediate consequence is pressure on manufacturers to reassess supplier portfolios, accelerate qualification of domestic vendors, or absorb cost increases through internal margin adjustments.

Hospitals and ambulatory surgical centers respond to higher device acquisition costs by seeking stronger value propositions, longer device longevity assurances, bundled service contracts, and clearer evidence of reduced downstream utilization. Payers meanwhile intensify scrutiny of reimbursement pathways and may require more robust real-world outcomes data to justify higher payments. To preserve competitiveness, device developers pursue a combination of strategies including supplier diversification, localizing critical manufacturing steps, redesigning products to reduce cost-sensitive inputs, and negotiating longer-term supply agreements to hedge volatility.

Regulatory and procurement teams must also account for potential lead-time variability and customs-related delays; this amplifies the importance of inventory planning and contingency sourcing. In aggregate, tariffs act as a catalyst for deeper supply chain resilience planning and may accelerate strategic moves toward regional manufacturing hubs, without fundamentally altering the clinical rationale for mechanical circulatory support.

Delineating actionable segmentation insights across device type, application, technology, end users and patient demographics to inform product design, clinical adoption and go-to-market strategies

A granular segmentation lens clarifies where clinical need, technology capability and commercial opportunity align. Based on Type, market analysis differentiates between Total Artificial Heart and Ventricular Assist Device, with the Ventricular Assist Device category further subdivided into Biventricular Assist Device, Left Ventricular Assist Device, and Right Ventricular Assist Device to reflect differing clinical indications and implantation complexity. Each device subtype entails distinct engineering trade-offs, follow-up requirements and clinical training programs, which shape adoption patterns across care settings.

Based on Application, the distinction between Bridge To Transplant and Destination Therapy highlights divergent evidence expectations: Bridge To Transplant usage relies heavily on short-to-intermediate term reliability and compatibility with transplant pathways, whereas Destination Therapy demands long-term durability and quality-of-life metrics. Based on Technology, axial, centrifugal, electromagnetic and pneumatic platforms each present unique profiles in terms of hemocompatibility, power consumption and implant footprint, informing which patient populations and clinical scenarios they best serve. Based on End User, the variance among Ambulatory Surgical Centers, Hospitals and Specialty Clinics affects procedural throughput, perioperative staffing models and capital acquisition decisions. Finally, Based on Patient Group, differences between Adults and Pediatrics require tailored device sizing, physiological considerations and specialized clinical protocols. When integrated, these segmentation dimensions guide prioritized product development, targeted clinical trials and differentiated commercial strategies.

Uncovering critical regional considerations across the Americas, Europe Middle East and Africa, and Asia Pacific to align regulatory pathways, reimbursement models and commercialization plans

Regional dynamics materially influence regulatory timelines, reimbursement approaches and clinical uptake. In the Americas, concentrated centers of excellence, established transplant programs and mature hospital procurement processes create fertile ground for high-cost, high-complexity devices, while regional payers increasingly demand robust outcomes evidence to authorize reimbursement. North American clinical networks also tend to drive innovation adoption when led by influential academic centers, and procurement-led group purchasing can accelerate scale deployment across health systems.

In Europe, Middle East & Africa, regulatory fragmentation and heterogeneous reimbursement models shape a more phased adoption curve, with leading national health systems often piloting new technologies before broader roll-out. Reimbursement in several European markets hinges on health technology assessment outcomes and negotiation with national payers, which emphasizes the need for early engagement and real-world data generation. Regionally, countries in the Middle East and Africa present divergent infrastructure readiness and financing mechanisms, necessitating tailored market-entry strategies.

Across Asia-Pacific, rapid expansion of specialized cardiac centers, growing domestic medtech capabilities, and diverse payer landscapes create both competitive pressure and partnership opportunities. Several markets in the region favor local manufacturing partnerships and technology transfer agreements to support scale, while others prioritize fast regulatory pathways for devices addressing significant unmet clinical need. Recognizing these regional contrasts allows stakeholders to sequence market entry, evidence generation and commercial investments to maximize clinical impact and return on effort.

Highlighting competitive and collaborative company-level developments, strategic partnerships, IP trajectories, and investment patterns shaping leadership in the artificial heart ecosystem

Company-level activity in the artificial heart domain is characterized by a dual track of sustained investment from established medical device manufacturers and nimble innovation from specialized startups and academic spin-outs. Incumbent firms typically focus on incremental improvements to enhance reliability, reduce adverse events, and expand indications through clinical studies. Meanwhile, smaller companies and university-affiliated teams often pursue disruptive concepts-novel pump architectures, alternative energy transfer mechanisms, or biomaterials that minimize host response-which can become attractive targets for strategic partnerships or licensing deals.

Strategic collaborations are a recurring theme: clinical partnerships accelerate access to real-world data, contract manufacturing and supply chain alliances mitigate production risk, and co-development agreements with technology companies enhance telemetry and analytics capabilities. Intellectual property strategies, including targeted patenting and defensive portfolios, differentiate market positioning and influence M&A activity. Investment patterns show growing interest in platform technologies that enable modular upgrades, as well as services that bundle device provision with remote monitoring and outcomes management. Competitive advantage increasingly depends on integrated solutions that combine device performance with ecosystem services, regulatory acumen and scalable manufacturing.

Presenting actionable recommendations for device manufacturers, clinical leaders and payers to accelerate adoption, optimize value propositions and mitigate supply chain and regulatory friction

Industry leaders can take several pragmatic actions to accelerate adoption and safeguard commercial momentum. Manufacturers should prioritize modular design principles that reduce dependence on tariff-sensitive components and simplify regulatory submissions for incremental improvements. Establishing validated secondary suppliers and qualifying local manufacturing partners will reduce exposure to supply chain shocks while preserving time-to-market. Concurrently, investing in telemetry and outcomes platforms creates defensible differentiation by generating the real-world evidence payers and health systems increasingly require.

Clinical leaders should codify standardized implantation and follow-up pathways that capture consistent patient-reported and clinical outcomes, enabling comparative effectiveness assessments and supporting reimbursement discussions. Early engagement with payers to define value metrics, bundled payment options, and risk-sharing arrangements will facilitate smoother adoption. Payers and hospital systems should pilot payment models that align reimbursement with demonstrated reductions in readmissions, length of stay and downstream interventions, while ensuring patient access for high-need cohorts.

Across the ecosystem, stakeholders should collaborate on registries and cross-institutional data-sharing initiatives to accelerate evidence generation. A coordinated approach to regulatory strategy, supply chain resilience and value demonstration will materially increase the probability of sustained clinical adoption and commercial success.

Describing a rigorous mixed-methods research methodology blending clinical evidence appraisal, stakeholder interviews, supply chain analysis and regulatory mapping to ensure robust market intelligence

This research deploys a mixed-methods methodology designed to triangulate clinical, commercial and regulatory perspectives and produce robust, actionable intelligence. The approach begins with a comprehensive appraisal of peer-reviewed clinical literature, regulatory filings and published guidance to establish the evidence base for device safety, efficacy and indications. That foundation is complemented by structured interviews with a representative sample of stakeholders including cardiothoracic surgeons, heart failure specialists, hospital procurement leaders, payers and device engineers to capture experiential insight and operational constraints.

Supply chain analysis maps critical component flows, manufacturing dependencies and potential chokepoints, while regulatory mapping compares approval and post-market surveillance expectations across major jurisdictions. Where available, anonymized real-world data and registry summaries inform assessments of utilization patterns and outcomes. Findings are validated through cross-checks with industry experts and methodical reconciliation of qualitative and quantitative inputs. Throughout the process, emphasis is placed on transparency of assumptions, reproducibility of findings and clear articulation of limitations to ensure that end-users can confidently apply insights to strategic decisions.

Concluding insights that synthesize technological, regulatory and commercial trajectories to guide strategic decision-making and future investment priorities within the artificial heart domain

The convergence of technological maturation, evolving clinical protocols and shifting commercial dynamics positions artificial heart technologies at an inflection point. Advances in device engineering and telemetry are steadily reducing traditional barriers to broader adoption, while regional regulatory and reimbursement environments continue to shape the pace and pattern of uptake. Supply chain pressures and trade policy changes add complexity that organizations must proactively manage through diversification and near-term operational planning.

Strategically, the most successful stakeholders will be those that integrate product innovation with comprehensive evidence generation, resilient manufacturing strategies and payer-aligned value propositions. Collaboration across clinical, engineering and commercial teams will accelerate the translation of laboratory progress into clinical best practice. As devices become more embedded within longitudinal care models, the ability to demonstrate meaningful improvements in patient-centered outcomes and system-level efficiencies will determine which technologies achieve durable adoption and scale. This synthesis underscores the need for deliberate, data-driven action to realize the transformative potential of artificial heart solutions across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Heart Market, by Type

  • 8.1. Total Artificial Heart
  • 8.2. Ventricular Assist Device
    • 8.2.1. Biventricular Assist Device
    • 8.2.2. Left Ventricular Assist Device
    • 8.2.3. Right Ventricular Assist Device

9. Artificial Heart Market, by Application

  • 9.1. Bridge To Transplant
  • 9.2. Destination Therapy

10. Artificial Heart Market, by Technology

  • 10.1. Axial
  • 10.2. Centrifugal
  • 10.3. Electromagnetic
  • 10.4. Pneumatic

11. Artificial Heart Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Artificial Heart Market, by Patient Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Artificial Heart Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Heart Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Heart Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Heart Market

17. China Artificial Heart Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed, Inc.
  • 18.7. Berlin Heart GmbH
  • 18.8. BIOTRONIK SE & Co. KG
  • 18.9. BiVACOR Inc.
  • 18.10. Boston Scientific Corporation
  • 18.11. Calon Cardio-Technology Ltd.
  • 18.12. CARMAT SA
  • 18.13. CorWave SA
  • 18.14. CryoLife, Inc.
  • 18.15. Edwards Lifesciences Corporation
  • 18.16. Evaheart, Inc.
  • 18.17. FineHeart SA
  • 18.18. Getinge AB
  • 18.19. Jarvik Heart, Inc.
  • 18.20. Lepu Medical Technology Beijing Co., Ltd.
  • 18.21. LivaNova PLC
  • 18.22. Medtronic plc
  • 18.23. MicroPort Scientific Corporation
  • 18.24. RealHeart AB
  • 18.25. ReliantHeart, Inc.
  • 18.26. Siemens Healthineers
  • 18.27. Sun Medical Technology R&D Co., Ltd
  • 18.28. SynCardia Systems, LLC
  • 18.29. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL HEART MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL HEART MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)